The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

SS-31 Dosage Guide

SS-31 (Elamipretide) is a mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. Research focuses on cardiac function, heart failure, and mitochondrial disease.

Standard Research Dosage

0.05–0.25 mg/kg body weight, administered subcutaneously once daily. Clinical trials for heart failure (PROGRESS-HF) used 40 mg/day subcutaneous infusion. Research protocols typically use 5–20 mg/day.

Mechanism of Action

SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain and reducing reactive oxygen species (ROS) production. This mechanism is distinct from other antioxidants and is specific to mitochondrial membranes.

Clinical Trial Record

PROGRESS-HF Phase 2 trial showed encouraging signals in HFpEF. However, the pivotal Phase 3 MMPOWER-3 trial (primary mitochondrial myopathy; Neurology 2023, n≈218) did not meet its primary endpoint. A separate heart failure program (MMPOWER-HF) also did not demonstrate efficacy. Human efficacy is not established.